Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Shares Dip After Halt Of Birinapant Trial

After Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) took the decision to stop the progress of the Birinapant hepatitis B drug trial in its phase 1 due to some safety issues, the company has suffered another blow after it plunged at the stock markets. Reportedly, the phase 1 trials involved analysis of the drug doses to fight the […]

Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Announces Publication of Preclinical Characterization of Birianapant

Boston, MA 04/01/2014 (wallstreetpr)  – morning trading session, moving up by highs of $18.65%. The huge gains comes at the back of Tetralogic announcing that data published in the April issue of Molecular Cancer Therapeutics, further advances the company’s lead SMAC-Mimetic Birianapant. The product is currently under Phase 1 and Phase II clinical trials in […]